The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

31 Mar 2015 07:00

RNS Number : 9231I
Frontier IP Group plc
31 March 2015
 



 

 

AIM: FIPP

 

 

Frontier IP Group Plc

("Frontier IP" or "the Company")

 

Frontier IP specialises in assisting universities, research institutions and companies in the commercialisation and exploitation of their Intellectual Property.

 

Half year results for the six months to 31 December 2014

 

KEY POINTS

 

· Fair value of the portfolio at 31 December 2014 increased to £1,574,000 - an increase of 19% from 30 June 2014 (30 June 2014: £1,325,000) and an increase of 68% from 31 December 2013 (31 December 2013: £937,000)

 

· Total revenue decreased to £244,000 (2013: £345,000) - principally reflecting a lower gain on the revaluation of investments of £160,000 (2013: £243,000)

 

· Revenue from services of £84,000 (2013: £92,000)

 

· Loss before tax of £242,000 (2013: profit of £3,000)

 

· Basic loss per share of 1.07p (2013: basic earnings per share of 0.02p)

 

· Cash balances as at 31 December 2014 of £184,000 (30 June 2014: £587,000; 31 December 2013: £992,000)

 

· Net assets per share as at 31 December 2014 of 17p (30 June 2014: 18p; 31 December 2013: 18p)

 

· Further progress in the portfolio including:

- first spin-out company from the University of Cambridge - 40% shareholding

- successful fundraising completed for portfolio company, Nandi Proteins

 

· Post period-end

- Added new portfolio company Cambridge Sensor Technologies Limited, bringing the total number of portfolio companies to 17

- Portfolio company, Alusid Limited, announced its first fundraising

 

· Opportunities continue to be encouraging

 

Andrew Richmond, Chairman, commented,

 

"I am pleased to report that we made good progress over the first half of the financial year, in line with our strategy. We continued to pursue the growth of our portfolio and this was reflected in a 19% increase in the fair value of our portfolio compared to 30 June 2014 and in a 68% increase compared to 31 December 2013.

 

We also extended our access to sources of IP and added our first spin-out company from the University of Cambridge. We saw encouraging developments across our existing portfolio over the six months, including a sizeable fundraising for Nandi Proteins. We are also pleased to note continued progress in the second half so far as, post period-end, we have added a further portfolio company, Cambridge Sensor Technologies, and announced a fundraising for portfolio company Alusid.

 

Looking ahead, we expect to see further progress in our portfolio and remain very positive about the growth opportunities available to us."

 

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

CHAIRMAN'S STATEMENT

Introduction

 

Frontier IP's growth strategy is built on generating value from its university relationships by becoming closely and actively involved in advising on the commercialisation of innovative IP. In exchange for providing our commercialisation and fundraising skills, Frontier IP receives equity shareholdings in university spin-out companies. The Company's goal is to develop a portfolio of companies which have the potential for significant value on exit and where we have strong industry experience. Currently, Frontier IP's portfolio totals 17 companies, at a range of stages of maturity.

 

I am pleased to report that we made good progress over the first half of the financial year, in line with our strategy. We continued to pursue the growth of our portfolio and this was reflected in a 19% increase in the fair value of our portfolio compared to 30 June 2014 and in a 68% increase compared to 31 December 2013. We have also extended our access to sources of IP and added a new portfolio company from the Department of Chemical Engineering and Biotechnology at the University of Cambridge, Cambridge Simulation Solutions Limited. Post period-end, we added a further portfolio company, Cambridge Sensor Technologies Limited, created to exploit technology developed by Dr. Mark Williamson, a lecturer and researcher at the same department at the University of Cambridge. Our 40% shareholdings in both companies represent significant positions and we are delighted to be engaged in the task of maximising the commercial potential of the very exciting technology which resides in both companies.

 

We saw encouraging developments across our existing portfolio companies over the six months, including a sizeable fundraising for Nandi Proteins Limited. Post period-end, we announced a further portfolio company fundraising for Alusid Limited.

 

Looking ahead, we expect to see further progress in our portfolio over the remainder of the financial year.

 

Results

 

Financial assets at fair value through profit and loss at 31 December 2014 increased to £1,574,000 (30 June 2014: £1,325,000; 31 December 2013: £937,000). Revenue from services over the first half decreased marginally to £84,000 (2013: £92,000) while the decrease in total revenue to £244,000 (2013: £345,000) largely reflected lower investment revaluations. The revaluation of investments (unrealised) totaled £160,000 (2013: £243,000). There was no dividend income in the first half against dividend income of £10,000 in the comparative period. The loss before tax was £242,000 (2013: profit £3,000). Reflecting the investment we have made in strengthening the management team, ongoing administrative expenses increased to £487,000 (2013: £316,000), with professional fees also affecting overheads. The basic loss per share was 1.07p (2013: earnings per share of 0.02p).

 

Cash balances stood at £184,000 as at 31 December 2014 (2013: £992,000). Net assets per share as at 31 December 2014 were 17p (30 June 2014: 18p; 31 December 2013: 18p).

 

Operational Review

 

During the period, we were pleased to add our first spin-out company from the University of Cambridge, Cambridge Simulation Solutions Limited ("CSS"). CSS has been formed to exploit technology developed by Dr. Vassilios Vassiliadis, a Senior Lecturer at the Department of Chemical Engineering and Biotechnology, who has developed a method to simulate and control complex chemical processes. Frontier IP received a 40% equity stake in CSS.

Post period-end, we were pleased to add a further portfolio company, Cambridge Sensor Technologies Limited ("CST"). CST was formed to exploit the technology developed by Dr. Mark Williamson, a lecturer and researcher at the Department of Chemical Engineering and Biotechnology at the University of Cambridge. CST develops heating system, sensors and control strategies for industrial processes in which the composition of the processing atmosphere is important. Frontier IP received a 40% equity stake in CST.

 

We have seen encouraging developments in a number of our portfolio companies over the period. In November 2014, drug discovery company ex scientia Ltd announced that it has signed a major collaboration agreement with Sunovion Pharmaceuticals Inc. to collaborate on the discovery and optimisation of novel medicines for psychiatric disorders. This agreement included an upfront payment of $1 million (USD) to ex scientia Ltd. Also in November, Nandi Proteins Limited completed a capital restructuring and funding round totaling £660,000 (gross), following which the Company's equity holding increased to 21%.

 

In March 2015, portfolio company Alusid Limited ("Alusid") announced its first funding, receiving commitments totaling £266,000, which will be invested in two tranches. Following this investment round, Frontier IP's holding in Alusid will be revalued and will show an uplift of over £0.68 million. Frontier IP will hold 39% of the issued share capital of Alusid following the investment of the second tranche. The revaluation will be recognised in Frontier IP's Annual Report & Financial Statements for the year ending 30 June 2015.

 

We continue to work with our existing and new partners in sourcing and identifying potentially valuable IP and are working on a range of pipeline projects.

 

Outlook

 

Frontier IP has made encouraging progress over the first half and the continuing growth of our portfolio is especially pleasing. We remain very positive about the growth opportunities available to us and look forward to reporting on further portfolio progress over the second half of the financial year.

 

Andrew Richmond

Non-executive Chairman

30 March 2015

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 

For the six months ended 31 December 2014

 

 

 

 

Notes

Six months ended 31 December 2014 (unaudited)

 Six months ended 31 December 2013 (unaudited)

Year ended 30 June 2014 (audited)

£'000

£'000

£'000

Revenue

Revenue from services

84

92

178

Other operating income

Unrealised profit on the revaluation of

investments

7

160

243

608

Dividend income on financial assets at fair

value through profit or loss

-

10

10

Total revenue

244

345

796

 

Administrative expenses

(487)

(316)

(769)

Placing costs

-

(26)

-

(Loss)/profit from operations

(243)

3

27

Interest income on short-term bank deposits

1

-

-

(Loss)/profit before tax

(242)

3

27

Taxation

5

-

-

-

(Loss)/profit and total comprehensive (expense)/income attributable to the equity holders of the parent

 

(242)

 

3

27

(Loss)/profit per share attributable to the equity

holders of the Company

Basic (loss)/earnings per share

6

(1.07)p

0.02p

0.13p

Diluted (loss)/earnings per share

6

(1.05)p

0.02p

0.13p

 

 

All of the Group's activities are classed as continuing and there were no comprehensive gains or losses in any period other than those included in the statement of comprehensive income.

 

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 

At 31 December 2014

 As at 31 December

2014 (unaudited)

£'000

 As at 31 December

2013 (unaudited)

£'000

As at

30 June

2014 (audited)

£'000

ASSETS

Notes

Non-current assets

Tangible fixed assets

2

-

2

Goodwill

1,966

1,966

1,966

Financial assets at fair value through profit and loss

7

1,574

937

1,325

3,542

2,903

3,293

Current assets

Trade receivables and other current assets

Cash and cash equivalents

 

229

184

 

224

992

 

299

587

413

1,216

886

Total assets

3,955

4,119

4,179

LIABILITIES

Current liabilities

Trade and other payables

(119)

(77)

(110)

(119)

(77)

(110)

 

Net assets

 

3,836

 

4,042

 

4,069

EQUITY

Called up share capital

Share premium account

Reverse acquisition reserve

Share based payment reserve

Retained earnings

2,253

4,794

(1,667)

134

(1,678)

2,253

4,794

(1,667)

122

(1,460)

2,253

4,794

(1,667)

125

(1,436)

 

Total equity

 

3,836

 

4,042

 

4,069

 

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six month period ended 31 December 2014

 

 

 

Share

 capital

 

Share

premium

account

 

Reverse acquisition

 reserve

Share-

based

payment

 reserve

 

Profit

and loss

account

 

 

 

Total

£'000

£'000

£'000

£'000

£'000

£'000

At 1st July 2013

1,305

4,457

(1,667)

119

(1,463)

2,751

Issue of shares for cash

767

375

-

-

-

1,142

Issue of shares in share swap

 

181

 

-

 

-

 

-

 

-

 

181

Cost of share issue

-

(38)

-

-

-

(38)

Profit for the period

-

-

-

-

3

3

Share-based payments

-

-

-

3

-

3

At 31 December 2013

2,253

4,794

(1,667)

122

(1,460)

4,042

Profit for the period

-

-

-

-

24

24

Share-based payments

-

-

-

3

-

3

At 30 June 2014

2,253

4,794

(1,667)

125

(1,436)

4,069

Loss for the period

-

-

-

-

(242)

(242)

Share-based payments

-

-

-

9

-

9

At 31 December 2014

2,253

4,794

(1,667)

134

(1,678)

3,836

 

 

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 31 December 2014

Six months ended 31 December

2014 (unaudited)

£'000

Six months ended 31 December

2013 (unaudited)

£'000

Year ended 30 June

2014 (audited)

£'000

Cash flows from operating activities

Cash used in operations

(315)

(222)

(617)

Taxation paid

-

-

-

Net cash used in operating activities

(315)

(222)

(617)

Cash flows from investing activities

Purchase of tangible fixed assets

-

-

(3)

Purchase of financial assets at fair value through profit and loss

 

(89)

 

(19)

 

(26)

Interest received

1

-

-

Net cash used in investing activities

 

(88)

(19)

(29)

 

Cash flows from financing activities

Proceeds from issue of equity shares

Costs of share issue

 

 

-

-

 

 

1,142

(64)

 

 

1,142

(64)

Net cash generated from financing activities

-

1,078

1,078

 

Net (decrease)/increase in cash and cash equivalents

 

(403)

 

837

 

432

Cash and cash equivalents at beginning of period

587

155

155

Cash and cash equivalents at end of period

184

992

587

Cash used in operations

(Loss)/profit before tax

(242)

3

27

Adjustments for:

Equity-based payments

9

3

6

Depreciation

-

-

1

Costs of share issue

-

26

26

Fair value (gain) on financial assets at fair value through profit or loss

 

(160)

 

(243)

 

(608)

Changes in working capital:

Trade and other receivables

224

(2)

(93)

Trade and other payables

(146)

(9)

24

(315)

(222)

(617)

 

 

NOTES

1. General information

 

The Company is a limited liability company incorporated in England and with its registered office at NorthWest Wing, Bush House, Aldwych, London WC2B 4EZ. The Company's trading office is situated at 93 George Street, Edinburgh EH2 3ES.

 

The Company is quoted on AIM market.

 

This condensed consolidated interim financial information was approved and authorised for issue by a duly appointed and authorised committee of the Board of Directors on 30 March 2015.

 

This condensed interim financial information has not been audited or reviewed by the Company's auditor.

 

2. Basis of preparation

 

This condensed consolidated interim financial information for the six months ended 31 December 2014 has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting". The condensed consolidated interim financial information should be read in conjunction with the annual financial statements for the year ended 30 June 2014, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU.

 

This condensed consolidated interim financial information does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The comparatives for the full year ended 30 June 2014 are not the Company's full statutory accounts for that year. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified, contained an emphasis of matter with respect to going concern, and did not contain a statement under sections 498(2) or 498(3) of the Companies Act 2006.

 

3. Accounting policies

 

The accounting policies applied by the Group in these unaudited half year results are consistent with those applied in the annual financial statements for the year ended 30 June 2014 as described in the Group's Annual Report for that year and as available on our website www.frontierip.co.uk. No new standards that have become effective in the period have had a material effect on the Group's financial statements.

 

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

 

4. Segmental information

 

The chief operating decision-maker has been identified as the Group's board of directors. The board reviews the Group's internal reporting in order to assess performance and allocate resources. Currently the Group has one operating activity, the commercialisation of University IP. All of the Group's activities are carried out in the UK.

 

5. Taxation

 

The taxation expense is recognised based on management's best estimate of the weighted average annual tax rate expected for the full financial year. Management expects that there will be no tax charge arising in the year and so there is no charge to taxation for the six months to 31 December 2014 (2013: Nil).

 

A deferred tax asset has not been recognised in respect of losses in view of the uncertainty as to the level of future taxable profits.

 

6. (Loss)/earnings per share

 

The calculation of the basic (loss) / earnings per share for the six months ended 31 December 2014 and 31 December 2013 and for the year ended 30 June 2014 is based on the (losses) / earnings attributable to the shareholders of Frontier IP Group Plc in each period divided by the weighted average number of shares in issue during the period.

 

Basic (loss)/earnings per share

 

(Loss) / earnings attributable to shareholders

Weighted average number of shares

 

Basic (loss) / earnings

per share

£'000

Number

Pence

Six months ended 31 December 2014

(242)

22,534,353

(1.07)

Six months ended 31 December 2013

3

17,689,331

0.02

Year ended 30 June 2014

27

20,091,931

0.13

Diluted (loss)/earnings per share

 

(Loss) / earnings attributable to shareholders

Weighted average number of shares

 

Diluted (loss) / earnings

per share

£'000

Number

Pence

Six months ended 31 December 2014

(242)

23,112,885

(1.05)

Six months ended 31 December 2013

3

17,689,331

0.02

Year ended 30 June 2014

27

20,091,931

0.13

 

As the Group is loss making in this period, all potentially dilutive shares are non-dilutive and therefore the weighted average number of shares for undiluted and diluted Earnings Per Share is the same.

 

7. Financial Assets at Fair Value Through Profit and Loss

 

31 December

30 June

31 December

2014

2014

2013

£'000

£'000

£'000

Opening balance

1,325

937

494

Additions

89

23

200

Fair value increase

160

365

243

Closing balance

1,574

1,325

937

 

8. Copies of Half Yearly Report

 

Copies of the Half Yearly Report will be available on the Company's website, www.frontierip.co.uk, and on request from the Company's offices at 93 George Street, Edinburgh EH2 3ES no later than 2nd April 2015.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR KBLFXEXFFBBB
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.